A Phase II Trial of the Effect of Perindopril on HFSR Incidence and Severity in Patients Receiving Regorafenib With Refractory Metastatic Colorectal Carcinoma (mCRC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Regorafenib (Primary) ; Perindopril
- Indications Colorectal cancer; Erythrodysaesthesia
- Focus Adverse reactions
- Acronyms PARICCA
- 11 Jul 2017 Planned End Date changed from 1 Jan 2019 to 1 Jan 2018.
- 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Dec 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2018.